S100A6 and prostate cancer: The pattern of S100A6 expression in benign epithelium and adenocarcinomas is similar to that of cytokeratin 5 and that reported for p63 and 34βE12, and therefore has the potential to be used as an adjuvant to these markers in the diagnosis of prostate cancer.